Chemotherapy After Diagnosis of Malignant Bowel Obstruction is Associated with Superior Survival for Medicare Patients with Advanced Malignancy

被引:10
作者
Bateni, Sarah B. [1 ]
Gingrich, Alicia A. [2 ]
Kirane, Amanda R. [2 ]
Sauder, Candice A. M. [2 ]
Gholami, Sepideh [2 ]
Bold, Richard J. [2 ]
Meyers, Frederick J. [3 ]
Canter, Robert J. [2 ]
机构
[1] Univ Toronto, Div Surg Oncol, Dept Surg, Toronto, ON, Canada
[2] Univ Calif Sacramento, Div Surg Oncol, Dept Surg, UC Davis Med Ctr, Sacramento, CA 95819 USA
[3] Univ Calif Sacramento, Div Hematol Oncol, Dept Internal Med, UC Davis Med Ctr, Sacramento, CA USA
关键词
D O I
10.1245/s10434-021-09831-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Although malignant bowel obstruction (MBO) often is a terminal event, systemic therapies are advocated for select patients to extend survival. This study aimed to evaluate factors associated with receipt of chemotherapy after MBO and to determine whether chemotherapy after MBO is associated with survival. Methods This retrospective cohort study investigated patients 65 years of age or older with metastatic gastrointestinal, gynecologic, or genitourinary cancers who were hospitalized with MBO from 2008 to 2012 using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Fine and Gray models were used to identify factors associated with receipt of chemotherapy accounting for the competing risk of death. Cox models identified factors associated with overall survival. Results Of the 2983 MBO patients, 39% (n = 1169) were treated with chemotherapy after MBO. No differences in receipt of chemotherapy between the surgical and medical patients were found in the univariable analysis (subdistribution hazard ratio [SHR], 0.96; 95% confidence interval [CI], 0.86-1.07; p = 0.47) or multivariable analysis (SHR, 1.12; 95% CI, 1.00-1.26; p = 0.06). Older age, African American race, medical comorbidities, non-colorectal and non-ovarian cancer diagnoses, sepsis, ascites, and intensive care unit stays were inversely associated with receipt of chemotherapy after MBO (p < 0.05). Chemotherapy with surgery was associated with longer survival than surgery (adjusted hazard ratio [aHR], 2.97; 95% CI, 2.65-3.34; p < 0.01) or medical management without chemotherapy (aHR, 4.56; 95% CI, 4.04-5.14; p < 0.01). Subgroup analyses of biologically diverse cancers (colorectal, pancreatic, and ovarian) showed similar results, with greater survival related to chemotherapy (p < 0.05). Conclusions Chemotherapy plays an integral role in maximizing oncologic outcome for select patients with MBO. The data from this study are critical to optimizing multimodality care for these complex patients.
引用
收藏
页码:7555 / 7563
页数:9
相关论文
共 50 条
[1]   Long-term Postprocedural Outcomes of Palliative Emergency Stenting vs Stoma in Malignant Large-Bowel Obstruction [J].
Abelson, Jonathan S. ;
Yeo, Heather L. ;
Mao, Jialin ;
Milsom, Jeffrey W. ;
Sedrakyan, Art .
JAMA SURGERY, 2017, 152 (05) :429-435
[2]   Practical recommendations for reporting Fine-Gray model analyses for competing risk data [J].
Austin, Peter C. ;
Fine, Jason P. .
STATISTICS IN MEDICINE, 2017, 36 (27) :4391-4400
[3]   Outcome Measures Other than Morbidity and Mortality for Patients with Incurable Cancer and Gastrointestinal Obstruction [J].
Badgwell, Brian ;
Krouse, Robert ;
Klimberg, Suzanne V. ;
Bruera, Eduardo .
JOURNAL OF PALLIATIVE MEDICINE, 2014, 17 (01) :18-26
[4]  
Bang YJ, 2010, LANCET, V376, P1302
[5]   Hospital utilization and disposition among patients with malignant bowel obstruction: a population-based comparison of surgical to medical management [J].
Bateni, Sarah B. ;
Gingrich, Alicia A. ;
Stewart, Susan L. ;
Meyers, Frederick J. ;
Bold, Richard J. ;
Canter, Robert J. .
BMC CANCER, 2018, 18
[6]   Increased Rates of Prolonged Length of Stay, Readmissions, and Discharge to Care Facilities among Postoperative Patients with Disseminated Malignancy: Implications for Clinical Practice [J].
Bateni, Sarah B. ;
Meyers, Frederick J. ;
Bold, Richard J. ;
Canter, Robert J. .
PLOS ONE, 2016, 11 (10)
[7]   Current perioperative outcomes for patients with disseminated cancer [J].
Bateni, Sarah B. ;
Meyers, Frederick J. ;
Bold, Richard J. ;
Canter, Robert J. .
JOURNAL OF SURGICAL RESEARCH, 2015, 197 (01) :118-125
[8]   Medical Therapy of Malignant Bowel Obstruction With Octreotide, Dexamethasone, and Metoclopramide [J].
Berger, Jeffrey ;
Lester, Paula ;
Rodrigues, Lucan .
AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE, 2016, 33 (04) :407-410
[9]   Malignant Bowel Obstruction: Natural History of a Heterogeneous Patient Population Followed Prospectively Over Two Years [J].
Chakraborty, Anita ;
Selby, Debbie ;
Gardiner, Kate ;
Myers, Jeff ;
Moravan, Veronika ;
Wright, Frances .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2011, 41 (02) :412-420
[10]   Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction [J].
Chouhan, Jay ;
Gupta, Rohan ;
Ensor, Joe ;
Raghav, Kanwal ;
Fogelman, David ;
Wolff, Robert A. ;
Fisch, Michael ;
Overman, Michael J. .
CANCER MEDICINE, 2016, 5 (02) :239-247